GlassScriptPhysician profile
Robert E Moulton
NPI 1720642929
$7,843.69
in general payments reported to CMS, 2019-2025
33 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,073 · 2023: $2,923 · 2024: $1,916 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,770.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,885.83 | 2022-2025 | |
| Novo Nordisk INC | $1,556.55 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $968.51 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $572.92 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $441.53 | 2023-2025 | |
| Lilly USA, LLC | $395.04 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.77 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $197.01 | 2022-2025 | |
| Astellas Pharma US INC | $193.53 | 2023-2024 | Veozah, Myrbetriq |
| Lundbeck LLC | $163.40 | 2023-2024 | Vyepti |
| Sanofi-Aventis U.S. LLC | $143.29 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $123.75 | 2022-2023 | |
| Dexcom, INC. | $115.55 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $83.98 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $72.77 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $71.51 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $66.74 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $56.31 | 2024 | Fanapt, Hetlioz |
| Abbott Laboratories | $55.77 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Ironwood Pharmaceuticals, INC | $51.75 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $45.78 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $45.40 | 2022-2023 | Krystexxa |
| Hologic Sales and Service, LLC | $45.09 | 2023-2025 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $41.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.42 | 2024 | Eliquis |
| Mylan Pharmaceuticals INC. | $32.56 | 2022 | |
| Corium, LLC | $31.03 | 2023 | Adlarity |
| Mannkind Corporation | $30.04 | 2023 | Afrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $25.68 | 2022 | |
| Mylan Specialty L.P. | $24.07 | 2024 | Yupelri |
| Viatris Specialty LLC | $16.38 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $15.20 | 2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.